Grunenthal

Metrion Biosciences joins human pain research consortium

Monday, August 29, 2016

Metrion Biosciences, a specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow, the University of St. Andrews, NHS Greater Glasgow & Clyde (NHS-GGC), Metrion Biosciences, the Grünenthal Group in Germany, and the U.K. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), with vital support and facilitation by NHS Blood & Transplant (Scotland). 

[Read More]

Grünenthal, Nordic Bioscience, Argenta collaborate

Wednesday, October 21, 2015

Germany-based Grünenthal, Denmark-based Nordic Bioscience and U.K.-based Argenta Discovery 2009, a Charles River company, are collaborating to improve the R&D of therapeutic approaches in multi-organ fibrosis. With a particular focus on fast-progressing patient subpopulations, the collaboration aims to develop new and improved preclinical and clinical assays to optimize the identification of new therapies.

[Read More]